RVMD
Source profileRevolution Medicines
RAS pathway oncology
Company profile
CIK1628171
ExchangeNASDAQ
SectorHealthcare
Tracked assets1
Pipeline assets
RMC-6236
Pancreatic ductal adenocarcinoma
Phase 2Phase 2 Readout
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | RAS(ON) inhibitor expansion cohort update Phase 2 Readout | RMC-6236 | Phase 2 | July 2026 | month | active |
SEC filings
Press releases
No sample press releases for this company.
ClinicalTrials.gov studies
No linked sample studies for this company.